Evidence map›Paper›PMID 35044875›Full record

ArticleTherapeutic advances in respiratory disease

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.

Fulvio Braido, Angelo G Corsico, Davide Paleari, Alessio Piraino, Luca Cavalieri, Nicola Scichilone

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Fulvio BraidoAssociate Professor of Respiratory Medicine University of Genoa Head of Respiratory Unit for continuity of care IRCCS Ospedale Policlinico San Martino - Genova.
Angelo G CorsicoDivision of Respiratory Diseases, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia 27100, Italy.
Davide PaleariMedical Affairs, Chiesi Italy. Chiesi Farmaceutici S.p.A. Parma, Italy.
Alessio PirainoMedical Affairs, Chiesi Italy. Chiesi Farmaceutici S.p.A. Parma, Italy.
Luca CavalieriMedical Affairs, Chiesi Italy. Chiesi Farmaceutici S.p.A. Parma, Italy.
Nicola ScichiloneDIBIMIS, University of Palermo, Palermo, Italy.
Chiesi (Italy) · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Genoa · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although bronchodilators are the cornerstone in chronic obstructive pulmonary disease (COPD) therapy, the treatment with a single-agent bronchodilator may not provide adequate symptoms control in COPD. The combination of drugs with different mechanisms of action may be more effective in inducing bronchodilation and preventing exacerbations, with a lower risk of side-effects in comparison with the increase of the dose of a single molecule. Several studies comparing the triple therapy with the association of long-acting ß

Indexed as

Pulmonary Disease, Chronic ObstructiveQuality of LifeAdministration, InhalationAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsDrug Therapy, CombinationFormoterol FumarateHumansMuscarinic AntagonistsAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsFormoterol FumarateMuscarinic AntagonistsCOPDinhaled extrafine formulationtriple therapy

Identifiers

PMID35044875
PMCPMC8796083
OpenAlexW4206064561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.